Literature DB >> 18055494

Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients.

Rudolf A Kley1, Yorck Hellenbroich, Peter F M van der Ven, Dieter O Fürst, Angela Huebner, Vera Bruchertseifer, Sören A Peters, Christoph M Heyer, Janbernd Kirschner, Rolf Schröder, Dirk Fischer, Klaus Müller, Karen Tolksdorf, Katharina Eger, Alfried Germing, Turgut Brodherr, Conny Reum, Maggie C Walter, Hanns Lochmüller, Uwe-Peter Ketelsen, Matthias Vorgerd.   

Abstract

Mutations in the filamin C gene (FLNC) cause a myofibrillar myopathy (MFM), morphologically characterized by focal myofibrillar destruction and abnormal accumulation of several proteins within skeletal muscle fibres. We studied 31 patients from four German families to evaluate the phenotype of filaminopathy. All patients harboured the same p.W2710X mutation in FLNC. Haplotype analysis suggested a founder mutation in these German filaminopathy families. The mean age at onset of clinical symptoms was 44 +/- 6 years (range, 24-57 years). Slowly progressive muscle weakness was mostly pronounced proximally, initially affecting the lower extremities and involving the upper extremities in the course of disease progression, similar to the distribution of weakness seen in limb-girdle muscular dystrophies (LGMD). Patients frequently developed respiratory muscle weakness. About one-third of the patients showed cardiac abnormalities comprising conduction blocks, tachycardia, diastolic dysfunction and left ventricular hypertrophy indicating a cardiac involvement in filaminopathy. Serum creatine kinase levels varied from normal up to 10-fold of the upper limit. Magnetic resonance imaging studies showed a rather homogenous pattern of muscle involvement in the lower extremities differing from that in other types of MFM. Myopathological features included perturbation of myofibrillar alignment, accumulation of granulofilamentous material similar to that seen in primary desminopathies and abnormal intracellular protein deposits typical of MFM. Decreased activities of oxidative enzymes and fibre hypertrophy seem to be early features, whereas dystrophic changes were present in advanced stages of filaminopathy. Rimmed vacuoles were detected in only a few cases. The intracellular aggregates were composed of a variety of proteins including filamin C, desmin, myotilin, Xin, dystrophin and sarcoglycans. Therapy is so far limited to symptomatic treatment. The German filaminopathy cohort, the largest group of patients studied so far, shares phenotypic features with LGMD and presents with characteristic histopathological findings of MFM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055494     DOI: 10.1093/brain/awm271

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  48 in total

Review 1.  Filamins in mechanosensing and signaling.

Authors:  Ziba Razinia; Toni Mäkelä; Jari Ylänne; David A Calderwood
Journal:  Annu Rev Biophys       Date:  2012-02-23       Impact factor: 12.981

2.  Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy.

Authors:  Montse Olivé; Zagaa Odgerel; Amaia Martínez; Juan José Poza; Federico García Bragado; Ramón J Zabalza; Ivonne Jericó; Laura Gonzalez-Mera; Alexey Shatunov; Hee Suk Lee; Judith Armstrong; Elías Maraví; Maria Ramos Arroyo; Jordi Pascual-Calvet; Carmen Navarro; Carmen Paradas; Mariano Huerta; Fabian Marquez; Eduardo Gutierrez- Rivas; Adolf Pou; Isidre Ferrer; Lev G Goldfarb
Journal:  Neuromuscul Disord       Date:  2011-06-14       Impact factor: 4.296

3.  Novel FLNC mutation in a patient with myofibrillar myopathy in combination with late-onset cerebellar ataxia.

Authors:  Giorgio Tasca; Zagaa Odgerel; Mauro Monforte; Stefania Aurino; Nigel F Clarke; Leigh B Waddell; Bjarne Udd; Enzo Ricci; Lev G Goldfarb
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

4.  Clinical reasoning: a 52-year-old woman with progressive proximal weakness.

Authors:  Sailaja Enduri; Matthew R G Taylor; Teerin Liewluck
Journal:  Neurology       Date:  2014-09-02       Impact factor: 9.910

5.  FLN-1/filamin is required to anchor the actomyosin cytoskeleton and for global organization of sub-cellular organelles in a contractile tissue.

Authors:  Charlotte A Kelley; Olivia Triplett; Samyukta Mallick; Kristopher Burkewitz; William B Mair; Erin J Cram
Journal:  Cytoskeleton (Hoboken)       Date:  2020-10-08

6.  ASB2α, an E3 ubiquitin ligase specificity subunit, regulates cell spreading and triggers proteasomal degradation of filamins by targeting the filamin calponin homology 1 domain.

Authors:  Ziba Razinia; Massimiliano Baldassarre; Gaia Cantelli; David A Calderwood
Journal:  J Biol Chem       Date:  2013-09-19       Impact factor: 5.157

Review 7.  Myofibrillar myopathies.

Authors:  Duygu Selcen
Journal:  Neuromuscul Disord       Date:  2011-01-20       Impact factor: 4.296

8.  FLNC Expression Level Influences the Activity of TEAD-YAP/TAZ Signaling.

Authors:  Anastasia Knyazeva; Aleksandr Khudiakov; Raquel Vaz; Aleksey Muravyev; Ksenia Sukhareva; Thomas Sejersen; Anna Kostareva
Journal:  Genes (Basel)       Date:  2020-11-13       Impact factor: 4.096

Review 9.  Myofibrillar myopathies.

Authors:  Duygu Selcen
Journal:  Curr Opin Neurol       Date:  2008-10       Impact factor: 5.710

10.  Distinct muscle imaging patterns in myofibrillar myopathies.

Authors:  D Fischer; R A Kley; K Strach; C Meyer; T Sommer; K Eger; A Rolfs; W Meyer; A Pou; J Pradas; C M Heyer; A Grossmann; A Huebner; W Kress; J Reimann; R Schröder; B Eymard; M Fardeau; B Udd; L Goldfarb; M Vorgerd; M Olivé
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.